Utama › Penyakit Hati › North Carolina
Kajian klinikal Penyakit Hati di North Carolina
6 kajian untuk Penyakit Hati sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
Observational Pharmaco-Epidemiology Research & Analysis
- Epividian, Durham
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 0 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT03813862A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Coastal Research Institute, Fayetteville
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- 89bio Clinical Study Site, Fayetteville
- dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 80 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Asheville
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06419374DILIN - Prospective Study
- Univeristy of North Carolina at Chapel Hill, Chapel Hill
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 2 ke atas · Semua jantina · Dikemas kini 8 Apr 2026 · NCT00345930A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Levine Cancer Institute, Charlotte
- Duke University Hospital, Durham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Dis 2025 · NCT06619561Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.